Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
Abstract Background Patients with advanced gastric cancer (AGC) have poor survival after first-line treatment containing an anti-programmed death-1/ligand 1 (PD-1/PD-L1) antibody. Accumulating evidence suggests rationales for continuing immunotherapy beyond progression, synergistic effects between i...
Saved in:
Main Authors: | Hidekazu Hirano, Naoki Takahashi, Yusuke Amanuma, Nobumi Suzuki, Daisuke Takahari, Takeshi Kawakami, Chie Kudo-Saito, Kengo Nagashima, Narikazu Boku, Ken Kato, Hirokazu Shoji |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-025-13591-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma
by: Daniel S. Alicea, MS, et al.
Published: (2025-03-01) -
Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
by: Xinyang Shen, et al.
Published: (2024-12-01) -
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01) -
Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01) -
Electroacupuncture alleviates paclitaxel-induced peripheral neuropathy by reducing CCL2-mediated macrophage infiltration in sensory ganglia and sciatic nerve
by: Yuanyuan Li, et al.
Published: (2025-01-01)